Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Study of efficacy and safety of bridging tx prior to CAR T in RRMM finds bispecific T-cell engager-based bridging, particularly talquetamab, achieved deepest responses & most effectively converted refractory dz B4 infusion.”
Title: Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma
Authors: Marie Christine Wesener, Uta Margareta Demel, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian von Tresckow, Marcel Teichert, Amelie Boquoi, Tobias Holderried, Friederike Schmitz, Fabian Müller, Friedrich-Linus Rößiger, Michele Hoffmann, Natalie Schub, Natalia Tovar, Aina Oliver-Caldes, Nicolaus Kröger, Ben-Niklas Baermann, Stephan Bohl, David Fandrei, Vladan Vucinic, Irene Strassl, Friedrich Stölzel, Carlos Fernández de Larrea, Ulrich Keller, Antonia Busse, Maximilian Merz, Nico Gagelmann
You can read the full article on the Haematologica.
You can find other articles featuring Robert Orlowski on OncoDaily.
